LifeMap Sciences launches
database of human cellular life for regenerative medicine
14 December 2012
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. has
launched LifeMap Discovery, a state-of-the-art roadmap of embryonic
development and stem cell biology.
The platform integrates embryonic development and stem cell
biology with molecular, cellular, anatomical, and disease-related
information, and provides data-mining capabilities and
LifeMap Discovery is tool for research and discovery in multiple
disciplines, including stem cell biology, developmental biology,
disease mechanisms and etiology, and drug and therapeutic discovery
and development. The database is a central element in LifeMap’s
discovery platform for biomedical and stem cell research, which also
includes GeneCards, the leading human gene database, and MalaCards,
the human disease database.
The platform is a central element in the generation of near-term
revenues through paid subscriptions, and is expected to drive
traffic to the recently launched LifeMap BioReagents marketing
portal, as well as aid in the company’s therapeutic discovery
Like GeneCards and MalaCards, LifeMap Sciences is making certain
aspects of LifeMap Discovery free for use to stem cell researchers
at academic non-profit organizations. Other institutions, including
pharmaceuticals and biotechnology companies, are offered access
through paid subscriptions to the platform.
The LifeMap integrated database suite is expected to drive
traffic to LifeMap Sciences’ LifeMap BioReagents portal, providing
hundreds of thousands of biomedical researchers who access these
databases a means of identifying research reagents that can enhance
their research and discovery efforts.
These databases currently feature targeted links to the various
BioTime PureStem human progenitor cell lines, PureStem packages, and
clinical- and research-grade human embryonic stem cell lines.
Starting in early 2013, additional links will be provided to
other research products that are complementary to the BioTime stem
cell products, which will be available from LifeMap BioReagents.
With access to the databases, researchers can become familiar with,
and purchase, products that relate directly to the types of genes,
cells, or diseases that they are investigating.
In addition to the generation of near-term revenues from
subscriptions and sales of research products, LifeMap Sciences’
scientific team is utilizing LifeMap Discovery to research and
identify PureStem human progenitor cell lines (also known as
ACTCellerate lines) likely to be useful in the research and
development of cell-based regenerative medicine therapies for a wide
range of diseases.
Once identified, selected cell lines will be marketed by LifeMap
Sciences for research purposes via the recently launched LifeMap
BioReagents portal, and these unique lines may eventually be
advanced to therapeutic development by BioTime and/or LifeMap
“The launch of the LifeMap Discovery database is a significant
milestone in the emerging field of regenerative medicine and a
tribute to the tireless efforts of the scientific and development
teams at LifeMap Sciences,” said Michael D. West, PhD, President and
Chief Executive Officer of BioTime.
“The power of embryonic stem cells to transform into all of
the cell types in the human body is at once both their greatest
opportunity and challenge. Many of the degenerative diseases
afflicting our aging population are caused by a lack of functional
cells capable of regenerating particular tissues in the body. Until
recently, the field has suffered from the lack of a 'roadmap'
directing scientists through the many hundreds of branch points in
the stems of the tree of human cellular life. Together with
GeneCards and MalaCards, LifeMap Discovery provides the beginning of
an online directory that may help us see the day when lifesaving
stem cell-based therapies reach the people so desperately in need of
"Over the past 18 months, our multidisciplinary team has put
forth tremendous effort to design and build an integrated,
cutting-edge database of embryonic development, stem cell research,
and regenerative medicine, tying together molecular, cellular,
anatomical, and disease-related information into one user-friendly
database,” said David Warshawsky, PhD, LifeMap Sciences’ Chief
“We expect LifeMap Discovery to have a profound effect on the
ability of researchers in academia and industry worldwide to advance
research in the stem cell field, and in other biomedical fields, and
to advance the ability to develop novel diagnostic and therapeutic
products and technologies.”